MNG632
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.488
- OXIDATIVE_PHOSPHORYLATION+0.390
- PROTEIN_SECRETION+0.378
- ALLOGRAFT_REJECTION+0.329
- UNFOLDED_PROTEIN_RESPONSE+0.302
- DNA_REPAIR+0.298
- E2F_TARGETS+0.272
- PEROXISOME+0.271
- IL6_JAK_STAT3_SIGNALING+0.269
- INTERFERON_ALPHA_RESPONSE+0.216
Top 10 suppressed
- ANGIOGENESIS-0.370
- KRAS_SIGNALING_DN-0.276
- APICAL_SURFACE-0.261
- CHOLESTEROL_HOMEOSTASIS-0.224
- WNT_BETA_CATENIN_SIGNALING-0.191
- MITOTIC_SPINDLE-0.184
- TNFA_SIGNALING_VIA_NFKB-0.171
- MYOGENESIS-0.153
- ESTROGEN_RESPONSE_EARLY-0.151
- NOTCH_SIGNALING-0.147
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG631 | — | — | 0.833 |
| 2 | BS_MT15SGJN | EPN | Supratentorial EPN | 0.792 |
| 3 | MNG784 | — | — | 0.787 |
| 4 | MNG389 | — | — | 0.781 |
| 5 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.774 |
| 6 | BS_WYERXS4G | EPN | Supratentorial EPN | 0.758 |
| 7 | MNG1169 | — | — | 0.753 |
| 8 | MNG781 | — | — | 0.752 |
| 9 | TCGA-46-3769-01A-01R-0980-07 | — | cohortA1 | 0.748 |
| 10 | MNG1170 | — | — | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.488 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.378 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.329 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.302 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.298 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.272 | Inavolisib | — uncovered |
| PEROXISOME | 0.271 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.269 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.216 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.214 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.189 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.188 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.185 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.183 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.165 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.162 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.138 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.133 | Inavolisib | — uncovered |